Stakeholders' Views on Barriers to Research on Controversial Controlled Substances

Evelyn Rhodes, Michael Andreae, Tyler Bourgiose, Debbie Indyk, Rosamond Rhodes, Henry Sacks

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Many diseases and disease symptoms still lack effective treatment. At the same time, certain controversial Schedule I drugs, such as heroin and cannabis, have been reputed to have considerable therapeutic potential for addressing significant medical problems. Yet, there is a paucity of U.S. clinical studies on the therapeutic uses of controlled drugs. For example, people living with HIV/AIDS experience a variety of disease- and medication-related symptoms. Their chronic pain is intense, frequent, and difficult to treat. Nevertheless, clinical trials of compassionate management for their chronic symptoms, which should be a research priority, are stymied. We employed qualitative methods to develop an understanding of the barriers to research on potential therapeutic uses of Schedule I drugs so that they might be addressed. We elicited the perspectives of key stakeholder groups that would be involved in such studies: people living with HIV/AIDS, clinicians, and members of institutional review boards. As we identified obstacles to research, we found that all of the stakeholder groups arrived at the same conclusion, that clinical research on the therapeutic potential of these drugs is ethically required.

Original languageEnglish (US)
Pages (from-to)308-321
Number of pages14
JournalThe Journal of clinical ethics
Volume27
Issue number4
StatePublished - Dec 1 2016

Fingerprint

Controlled Substances
stakeholder
drug
Therapeutic Uses
Disease
Research
Pharmaceutical Preparations
Appointments and Schedules
Acquired Immunodeficiency Syndrome
AIDS
HIV
Therapeutic Human Experimentation
Research Ethics Committees
Heroin
Cannabis
Chronic Pain
qualitative method
pain
medication
Group

All Science Journal Classification (ASJC) codes

  • Issues, ethics and legal aspects
  • Health(social science)
  • Health Policy

Cite this

Rhodes, E., Andreae, M., Bourgiose, T., Indyk, D., Rhodes, R., & Sacks, H. (2016). Stakeholders' Views on Barriers to Research on Controversial Controlled Substances. The Journal of clinical ethics, 27(4), 308-321.
Rhodes, Evelyn ; Andreae, Michael ; Bourgiose, Tyler ; Indyk, Debbie ; Rhodes, Rosamond ; Sacks, Henry. / Stakeholders' Views on Barriers to Research on Controversial Controlled Substances. In: The Journal of clinical ethics. 2016 ; Vol. 27, No. 4. pp. 308-321.
@article{fb3ece1cb0cb4744b3efcdeabc866c08,
title = "Stakeholders' Views on Barriers to Research on Controversial Controlled Substances",
abstract = "Many diseases and disease symptoms still lack effective treatment. At the same time, certain controversial Schedule I drugs, such as heroin and cannabis, have been reputed to have considerable therapeutic potential for addressing significant medical problems. Yet, there is a paucity of U.S. clinical studies on the therapeutic uses of controlled drugs. For example, people living with HIV/AIDS experience a variety of disease- and medication-related symptoms. Their chronic pain is intense, frequent, and difficult to treat. Nevertheless, clinical trials of compassionate management for their chronic symptoms, which should be a research priority, are stymied. We employed qualitative methods to develop an understanding of the barriers to research on potential therapeutic uses of Schedule I drugs so that they might be addressed. We elicited the perspectives of key stakeholder groups that would be involved in such studies: people living with HIV/AIDS, clinicians, and members of institutional review boards. As we identified obstacles to research, we found that all of the stakeholder groups arrived at the same conclusion, that clinical research on the therapeutic potential of these drugs is ethically required.",
author = "Evelyn Rhodes and Michael Andreae and Tyler Bourgiose and Debbie Indyk and Rosamond Rhodes and Henry Sacks",
year = "2016",
month = "12",
day = "1",
language = "English (US)",
volume = "27",
pages = "308--321",
journal = "Journal of Clinical Ethics",
issn = "1046-7890",
publisher = "Journal of Clinical Ethics",
number = "4",

}

Rhodes, E, Andreae, M, Bourgiose, T, Indyk, D, Rhodes, R & Sacks, H 2016, 'Stakeholders' Views on Barriers to Research on Controversial Controlled Substances', The Journal of clinical ethics, vol. 27, no. 4, pp. 308-321.

Stakeholders' Views on Barriers to Research on Controversial Controlled Substances. / Rhodes, Evelyn; Andreae, Michael; Bourgiose, Tyler; Indyk, Debbie; Rhodes, Rosamond; Sacks, Henry.

In: The Journal of clinical ethics, Vol. 27, No. 4, 01.12.2016, p. 308-321.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Stakeholders' Views on Barriers to Research on Controversial Controlled Substances

AU - Rhodes, Evelyn

AU - Andreae, Michael

AU - Bourgiose, Tyler

AU - Indyk, Debbie

AU - Rhodes, Rosamond

AU - Sacks, Henry

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Many diseases and disease symptoms still lack effective treatment. At the same time, certain controversial Schedule I drugs, such as heroin and cannabis, have been reputed to have considerable therapeutic potential for addressing significant medical problems. Yet, there is a paucity of U.S. clinical studies on the therapeutic uses of controlled drugs. For example, people living with HIV/AIDS experience a variety of disease- and medication-related symptoms. Their chronic pain is intense, frequent, and difficult to treat. Nevertheless, clinical trials of compassionate management for their chronic symptoms, which should be a research priority, are stymied. We employed qualitative methods to develop an understanding of the barriers to research on potential therapeutic uses of Schedule I drugs so that they might be addressed. We elicited the perspectives of key stakeholder groups that would be involved in such studies: people living with HIV/AIDS, clinicians, and members of institutional review boards. As we identified obstacles to research, we found that all of the stakeholder groups arrived at the same conclusion, that clinical research on the therapeutic potential of these drugs is ethically required.

AB - Many diseases and disease symptoms still lack effective treatment. At the same time, certain controversial Schedule I drugs, such as heroin and cannabis, have been reputed to have considerable therapeutic potential for addressing significant medical problems. Yet, there is a paucity of U.S. clinical studies on the therapeutic uses of controlled drugs. For example, people living with HIV/AIDS experience a variety of disease- and medication-related symptoms. Their chronic pain is intense, frequent, and difficult to treat. Nevertheless, clinical trials of compassionate management for their chronic symptoms, which should be a research priority, are stymied. We employed qualitative methods to develop an understanding of the barriers to research on potential therapeutic uses of Schedule I drugs so that they might be addressed. We elicited the perspectives of key stakeholder groups that would be involved in such studies: people living with HIV/AIDS, clinicians, and members of institutional review boards. As we identified obstacles to research, we found that all of the stakeholder groups arrived at the same conclusion, that clinical research on the therapeutic potential of these drugs is ethically required.

UR - http://www.scopus.com/inward/record.url?scp=85043723823&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043723823&partnerID=8YFLogxK

M3 - Article

C2 - 28001138

AN - SCOPUS:85043723823

VL - 27

SP - 308

EP - 321

JO - Journal of Clinical Ethics

JF - Journal of Clinical Ethics

SN - 1046-7890

IS - 4

ER -